Anonymous Online Speakers v. United States District Court for the District of Nevada

Southern District Court of New York Dismisses Securities Suit Against Ebix

Retrieved on:

Tuesday, July 18, 2023

Hindenburg Research, SDNY, IPO, Anonymous Online Speakers v. United States District Court for the District of Nevada, In re Opinions and Orders of This Court Containing Novel or Significant Interpretations of Law (2016), Weakness, District court, Plaintiff, Ebix

JOHNS CREEK, Ga., July 18, 2023 (GLOBE NEWSWIRE) -- Ebix, Inc. (NASDAQ: Ebix), today issued an informational release declaring that the United States Southern District Court State of New York (SDNY) yesterday issued a formal ruling in the matter of Ebix, Inc. (“Ebix”) vs. Rahul Saraf (the “Plaintiff”) and dismissed the class action securities suit against Ebix.

Key Points:

JOHNS CREEK, Ga., July 18, 2023 (GLOBE NEWSWIRE) -- Ebix, Inc. (NASDAQ: Ebix), today issued an informational release declaring that the United States Southern District Court State of New York (SDNY) yesterday issued a formal ruling in the matter of Ebix, Inc. (“Ebix”) vs. Rahul Saraf (the “Plaintiff”) and dismissed the class action securities suit against Ebix.
The District Court also denied the Plantiff’s request to file new amended claims, after reviewing the previous three complaints, and ordered the dismissal of the third amended complaint.
Ebix requested SDNY court for dismissal, arguing that, even with the new allegations, Plaintiff did not establish scienter (the validity of the allegations).
Earlier in this putative class action, the Plantiff had brought securities fraud claims against Ebix and two Ebix executives, Robin Raina and Steven Hamil (the “Individual Defendants”).

Enigma Software Group Prevails Over Malwarebytes at the Ninth Circuit

Retrieved on:

Tuesday, June 6, 2023

Bankruptcy Appellate Panel, Section 230, Constitutional right, United States Court of Appeals for the Ninth Circuit, First, Panel, District court, Education Act, Communications Decency Act, Malwarebytes, Inc. v. Enigma Software Group USA, LLC, Lanham Act, Anonymous Online Speakers v. United States District Court for the District of Nevada, First Amendment to the United States Constitution, Enigma

CLEARWATER, Fla. , June 6, 2023 /PRNewswire/ -- The U.S. Court of Appeals for the Ninth Circuit has ruled in favor of Enigma Software Group USA, LLC ("Enigma") that it can proceed with its lawsuit against Malwarebytes on its claims that Malwarebytes has engaged in anticompetitive conduct, false advertising under the Lanham Act and tortious interference with Enigma's business relations.

Key Points:

CLEARWATER, Fla. , June 6, 2023 /PRNewswire/ -- The U.S. Court of Appeals for the Ninth Circuit has ruled in favor of Enigma Software Group USA, LLC ("Enigma") that it can proceed with its lawsuit against Malwarebytes on its claims that Malwarebytes has engaged in anticompetitive conduct, false advertising under the Lanham Act and tortious interference with Enigma's business relations.
Enigma filed suit against Malwarebytes on claims of unfair trade practices, interference with business relations, and false advertising in connection with Enigma's claims that Malwarebytes had unlawfully blocked consumers from using Enigma's cybersecurity protection software products, thereby harming consumers and damaging Enigma.
This new Ninth Circuit ruling is the second time the Court of Appeals has rejected Malwarebytes' attempts to avoid responding to Enigma's claims.
Previously, the Ninth Circuit ruled that Malwarebytes was not protected from liability on Enigma's claims by Section 230 of the Communications Decency Act because Enigma adequately alleged Malwarebytes' anticompetitive conduct.

US Cybersecurity Firm Redbot Security Unmasks Malicious Insider Behind Internet Attacks

Retrieved on:

Tuesday, April 11, 2023

Defamation, Internet, IP, Privacy, CSAM, Bullying, Medicine, District court, KJK, Binder, Anonymous Online Speakers v. United States District Court for the District of Nevada, Social media, Cryptocurrency

DENVER, April 11, 2023 /PRNewswire/ -- Redbot Security, an industry-leading penetration testing company, announced on Tuesday that it has identified a potential perpetrator and is actively working, using legal processes, to uncover the identities of other malicious attackers behind a concerted internet smear campaign, designed to falsely disparage and defame the company.

Key Points:

The IP address of a former employee turned competitor has been linked to a sustained and vicious internet defamation and disparagement campaign against top cybersecurity company Redbot Security.
Through the efforts of Internet Defamation & Content Removal Attorney Ali Arko of KJK law firm, Redbot Security has obtained data linking at least some of the attacks to the IP address of a former Redbot Security employee who currently operates a competing business.
In response to these egregious attacks, Redbot Security filed a "John Doe" lawsuit in the District Court of Denver County against the anonymous individuals responsible.
Redbot Security has amended the complaint to name the former employee and his company as defendants.

Navidea Biopharmaceuticals Files Appeal in CRG Case

Retrieved on:

Thursday, December 1, 2022

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 2022, Navidea and its majority-owned subsidiary Macrophage Therapeutics, Inc. filed an appeal of the judgment by the District Court of Harris County, Texas in Case No.

Key Points:

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (Navidea or the Company), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on November 29, 2022, Navidea and its majority-owned subsidiary Macrophage Therapeutics, Inc. filed an appeal of the judgment by the District Court of Harris County, Texas in Case No.
v. Navidea Biopharmaceuticals, Inc. and Macrophage Therapeutics, Inc., with the 14th Court of Appeals of Texas for review by the appellate court.
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a biopharmaceutical company focused on the development of precision immunodiagnostic agents and immunotherapeutics.
The Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the first product developed and commercialized by Navidea based on the platform.

CV Sciences, Inc. Announces Proposed Settlement of Shareholder Litigation

Retrieved on:

Tuesday, September 27, 2022

On September 21, 2022, the District Court of Clark County, Nevada granted a motion for preliminary approval of the settlement agreement.

Key Points:

On September 21, 2022, the District Court of Clark County, Nevada granted a motion for preliminary approval of the settlement agreement.
The proposed settlement contemplates the implementation by the Company of certain corporate reforms and payment of $275,000 in attorneys' fees to plaintiffs.
Additional details regarding the proposed settlement are included in that Current Report on Form 8-K filed by CV Sciences with the Securities and Exchange Commission ("SEC") on September 27, 2022.
The Stipulation and Agreement of Settlement and Notice of Proposed Settlement ("Notice") are available at https://ir.cvsciences.com/governance-docs .

District Court Ruling In Favor Of David Semas' - METALAST® Trademark Against Chemeon For Breach of Contract Upheld By Ninth Circuit Court

Retrieved on:

Friday, July 29, 2022

NEWPORT BEACH, Calif., July 28, 2022 /PRNewswire/ -- On February 23, 2021 the United States District Court, District of Nevada, Reno (District Court) issued a Cease and Desist Injunction and ruled against metal finishing specialty chemical company Chemeon Surface Technology, LLC (Chemeon) of Minden, Nevada. Under court order this injunction prohibits the unlawful use in commerce by anyone of the name "Metalast®", a USPTO registered trademark owned by David Semas.

Key Points:

Under court order this injunction prohibits the unlawful use in commerce by anyone of the name "Metalast", a USPTO registered trademark owned by David Semas.
Chemeon appealed the District Court order and on June 2, 2022, with a Mandate issued on June 24, 2022 the Ninth Circuit Court of Appeals further upheld the District Court's FINDINGS OF FACT AND CONCLUSIONS OF LAW.
All products or piece parts surface treated or processed after that date cannot be labeled, and are not, nor have even been "formerly Metalast", or"formerly known as Metalast.
David Semas has not licensed or in any way otherwise or consented to the characterization of any business entity as being "Metalast.".

HUB Security Announces Share Buy-Back up to US$ 4.5 million

Retrieved on:

Thursday, June 2, 2022

TEL AVIV, Israel, June 2, 2022 /PRNewswire/ --The Board of Directors of HUB Cyber Security (Israel) Limited (TASE: HUB) approved the Company shares buy-back of up to a sum $4.5M (NIS 15 Million).

Key Points:

TEL AVIV, Israel, June 2, 2022 /PRNewswire/ --The Board of Directors of HUB Cyber Security (Israel) Limited (TASE: HUB) approved the Company shares buy-back of up to a sum $4.5M (NIS 15 Million).
HUB Cyber Security (Israel) Limited ("HUB") was established in 2017 by veterans of the 8200 and 81 elite intelligence units of the Israeli Defense Forces.
The company specializes in unique Cyber Security solutions protecting sensitive commercial and government information.
HUB operates in over 30 countries and provides innovative cybersecurity computing appliances as well as a wide range of cybersecurity services worldwide.

Eagle Pharmaceuticals Reaches Settlement Agreement with Hospira Related to BENDEKA® (bendamustine hydrochloride) until January 17, 2028

Retrieved on:

Tuesday, April 19, 2022

Anonymous Online Speakers v. United States District Court for the District of Nevada, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Research, CNS, GLOBE, Supreme court, Fresenius, Review, Eagle, Ciba-Geigy Canada Ltd v Apotex Inc, Forward-looking statement, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, FDA, Drug development, United States Court of Appeals for the Federal Circuit, Mylan, United States courts of appeals, Annual report, Compliance, Private Securities Litigation Reform Act, Justice, Company, Hospira, LLC, District, Orange, Intellectual property, Failure, Nasdaq, U.S. Department of Justice Office of Legislative Affairs, SEC, Law of the United Kingdom, Patent, Apotex, Phrase, Biotechnology, Lesbian flag, Orange Book, District court, Pharmaceutical industry, Bendamustine

WOODCLIFF LAKE, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that it has reached a settlement agreement with Hospira, Inc (Hospira).

Key Points:

WOODCLIFF LAKE, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that it has reached a settlement agreement with Hospira, Inc (Hospira).
Eagle had asserted two Orange Book-listed patents against Hospira related to its new drug application (NDA) referencing BENDEKA.
The settlement agreement provides that Hospira has the right to market its product beginning January 17, 2028, or earlier based on certain circumstances.
The settlement agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.

HCMC Announces Filing of Appeal to Ruling in Case Against Phillip Morris

Retrieved on:

Tuesday, December 14, 2021

As always, I would like to sincerely thank all of our valued shareholders for their continued support.

Key Points:

As always, I would like to sincerely thank all of our valued shareholders for their continued support.
Through its wholly owned subsidiary HCMC Intellectual Property Holdings, LLC, the Company manages and intends to expand on its intellectual property portfolio.
TheCompany currently operates sixretail vape stores in the Southeast region of the United States, through which it offers e-liquids,vaporizersand related products.
The Company also sells vitamins and supplements on its website TheVitaminStore.com.The Company markets its Q-Cup technology under the vape segment.

NCLA Contests Vague Rule that Unconstitutionally Chills Free Speech for Attorneys in Connecticut

Retrieved on:

Wednesday, November 10, 2021

The lack of clarity in the Rule deprives attorneys of the ability to discern what speech and conduct it proscribes, and thus they cannot know how to conform their speech in advance to the terms of the Rule.

Key Points:

The lack of clarity in the Rule deprives attorneys of the ability to discern what speech and conduct it proscribes, and thus they cannot know how to conform their speech in advance to the terms of the Rule.
Because Rule 8.4(7) regulates speech, attorneys will be forced to chill their speech on certain subjects to provide extra assurance that they will not be the targets of disciplinary proceedings.
The Rule also grants enforcement personnel too much discretion to decide what speech is sanctionable and what speech is not.
NCLA released the following statements:
Connecticuts Rule amounts to a speech code for lawyers.